Drugs / VRC-SRSDNA015-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00099463 | Dec 2004 → Aug 2007 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-SRSDNA015-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00099463 ↗ |
| Modality | Vaccine | “This is a Phase I open label study to evaluate safety, tolerability, and immune response of a recombinant DNA vaccine, VRC-SRSDNA015-00-VP.” NCT00099463 ↗ |
| Route | Intramuscular | “Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (in deltoid muscle) using the Biojector 2000 Needle-Free Injection Management System.” NCT00099463 ↗ |